A phase II trial testing the thermal dose parameter CEM43° T 90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy

  • P. D. Maguire, T. V. Samulski, L. R
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We prospectively evaluated whether delivering a thermal dose of >= 10 cumulative equivalent minutes at 43degreeC to > 90% of the tumour sites monitored (CEM43degreeT 90) would produce a pathologic complete response (pCR) in >= 75% of high-grade soft tissue sarcomas treated pre-operatively with thermoradiotherapy. The impact of thermal dose on local failure (LF), distant metastasis (DM), and toxicity was also assessed. Thirty-five patients >= 18 years old with grade 2 or 3 soft tissue sarcomas accessible for invasive thermometry were enrolled on the protocol. All patients received megavoltage external beam radiotherapy (RT) in daily fractions of 1.8-2.0 Gy, five times a week, to a median total dose of 50 Gy and an initial hyperthermia treatment (HT) of 1 h duration utilizing the BSD 2000 with Sigma 60 or MAPA applicators at frequencies of 60-140 MHz. Further HT was given for patients with CEM43degreeT 90 0.5 after initial HT ('heatable' patients), twice a week to a maximum of 10 HT or CEM43degreeT 90 100. Of the 35 patients entered, 30 had heatable tumours, one of which was inevaluable for pCR or LF as the patient died of DM prior to surgery, leaving 29 evaluable patients. Of these 29 patients, 15 (52%) had a pCR (95% CI: 37-73%), significantly less than the projected rate of >= 75% (p = 0.02). Of the 25 heatable tumours that achieved CEM43degreeT 90 = 10, 14 (56%) had a pCR (95% CI: 39-78%) significantly less than the projected rate (p = 0.06). Three of the 29 patients (10%) with heatable tumours had a LF, versus 1/5 unheatable tumours (p = 0.48). Fourteen of the 30 patients (47%) with heatable tumours developed DM, versus 2/5 unheatable tumours (p = 1.00). Ten of the 30 patients (33%) with heatable tumours developed treatment-induced toxicity. Thus, no correlation of thermal dose with histologic response was observed. Prospective control of CEM43degreeT 90 failed to achieve the projected pCR rate following pre-operative thermoradiotherapy for high-grade soft tissue sarcomas, despite excellent local control. Possible explanations for this outcome are discussed.

Cite

CITATION STYLE

APA

P. D. Maguire, T. V. Samulski, L. R. (2001). A phase II trial testing the thermal dose parameter CEM43° T 90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. International Journal of Hyperthermia, 17(4), 283–290. https://doi.org/10.1080/02656730121338

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free